CTLT vs. ROIV, RDY, ELAN, UTHR, LEGN, VKTX, CERE, SRPT, ASND, and JAZZ Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include Roivant Sciences (ROIV), Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), United Therapeutics (UTHR), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Cerevel Therapeutics (CERE), Sarepta Therapeutics (SRPT), Ascendis Pharma A/S (ASND), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
Catalent (NYSE:CTLT ) and Roivant Sciences (NASDAQ:ROIV ) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
In the previous week, Catalent had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 7 mentions for Catalent and 3 mentions for Roivant Sciences. Catalent's average media sentiment score of 1.11 beat Roivant Sciences' score of 0.94 indicating that Catalent is being referred to more favorably in the media.
Catalent has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
Roivant Sciences has a net margin of 3,624.14% compared to Catalent's net margin of -26.61%. Catalent's return on equity of -2.73% beat Roivant Sciences' return on equity.
Catalent received 598 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.00% of users gave Roivant Sciences an outperform vote while only 59.26% of users gave Catalent an outperform vote.
Catalent has higher revenue and earnings than Roivant Sciences. Catalent is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
64.8% of Roivant Sciences shares are owned by institutional investors. 0.3% of Catalent shares are owned by insiders. Comparatively, 4.6% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Catalent presently has a consensus target price of $52.46, suggesting a potential downside of 5.26%. Roivant Sciences has a consensus target price of $16.90, suggesting a potential upside of 50.49%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Catalent.
Summary Roivant Sciences beats Catalent on 11 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Catalent Competitors List
Related Companies and Tools
